Cargando…

Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation

Factor Xa (FXa) plays a significant role in the blood coagulation cascade and it has become a promising target for anticoagulation drugs. Three oral direct FXa inhibitors have been approved by the FDA for treating thrombotic diseases. By structure-activity relationship (SAR) analysis upon these FXa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wenzhi, Yuan, Jing, Fu, Xiaoli, Meng, Fancui, Zhang, Shijun, Xu, Weiren, Xu, Yongnan, Huang, Changjiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274369/ https://www.ncbi.nlm.nih.gov/pubmed/27089317 http://dx.doi.org/10.3390/molecules21040491

Ejemplares similares

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors
por: Huang, Changjiang, et al.
Publicado: (2017)

Anthranilamides with quinoline and β-carboline scaffolds: design, synthesis, and biological activity
por: Beus, Maja, et al.
Publicado: (2022)

Fragment-Based Lead Generation of 5-Phenyl-1H-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors
por: Wei, Qunchao, et al.
Publicado: (2018)

Tuning the Anthranilamide Peptidomimetic Design to Selectively Target Planktonic Bacteria and Biofilm
por: Kuppusamy, Rajesh, et al.
Publicado: (2023)

Novel Isosteviol-Based FXa Inhibitors: Molecular Modeling, In Silico Design and Docking Simulation
por: Gackowski, Marcin, et al.
Publicado: (2023)

Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation
por: Santana-Romo, Fabián, et al.
Publicado: (2020)

Green by Design: Convergent Synthesis, Computational Analyses, and Activity Evaluation of New FXa Inhibitors Bearing Peptide Triazole Linking Units
por: Rodríguez, Diego F., et al.
Publicado: (2021)

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking
por: Pu, Yinglan, et al.
Publicado: (2017)

Anthranilamide-based Short Peptides Self-Assembled Hydrogels as Antibacterial Agents
por: Aldilla, Vina R., et al.
Publicado: (2020)

Cyclocondensation of Anthranilamide with Aldehydes on Gallium-Containing MCM-22 Zeolite Materials
por: Sahu, Preeti, et al.
Publicado: (2021)

Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches
por: Lagos, Carlos F., et al.
Publicado: (2017)

Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes
por: Gill, Dipender, et al.
Publicado: (2020)

Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
por: Dutt, Tina, et al.
Publicado: (2020)

Antiviral Activity of Anthranilamide Peptidomimetics against Herpes Simplex Virus 1 and a Coronavirus
por: Urmi, Umme Laila, et al.
Publicado: (2023)

Characteristics of FXa-storing platelets in hemophilia B mice and the influence of alcohol on the platelets
por: Han, Wenwen, et al.
Publicado: (2023)

Direct Oral FXa Inhibitors Binding to Human Serum Albumin: Spectroscopic, Calorimetric, and Computational Studies
por: Mariño-Ocampo, Nory, et al.
Publicado: (2023)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

Anthranilamide-protected vinylboronic acid: rational monomer design for improved polymerization/transformation ability providing access to conventionally inaccessible copolymers
por: Suzuki, Hiroshi, et al.
Publicado: (2022)

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice
por: Pham, Phuong Tran, et al.
Publicado: (2019)

Hydrogels with intrinsic antibacterial activity prepared from naphthyl anthranilamide (NaA) capped peptide mimics
por: Aldilla, Vina R., et al.
Publicado: (2022)

Synthesis of a Novel Series of Amino Acid Prodrugs Based on Thienopyridine Scaffolds and Evaluation of Their Antiplatelet Activity
por: Lu, Nan, et al.
Publicado: (2018)

Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity
por: Amiral, Jean, et al.
Publicado: (2021)

Quantitative Structure–Activity Relationship Analysis of Isosteviol-Related Compounds as Activated Coagulation Factor X (FXa) Inhibitors
por: Gackowski, Marcin, et al.
Publicado: (2022)

A rapid construction of 1,3,2-benzodiazaborininones [R–B(aam)] from boronic acids and anthranilamides
por: Liao, Siwei, et al.
Publicado: (2023)

A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
por: Farkh, Carine, et al.
Publicado: (2021)

Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity
por: Narita, Yuki, et al.
Publicado: (2019)

Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
por: Zhang, Datong, et al.
Publicado: (2021)

Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Dutt, Tina, et al.
Publicado: (2020)

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage
por: McDonnell, Thomas, et al.
Publicado: (2022)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply
por: Hofmaenner, Daniel A., et al.
Publicado: (2022)

Synthesis of polyurethanes with pendant azide groups attached on the soft segments and the surface modification with mPEG by click chemistry for antifouling applications
por: Meng, Fancui, et al.
Publicado: (2018)

Design, Synthesis, and Biological Evaluation of PKD Inhibitors
por: George, Kara M., et al.
Publicado: (2011)

Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
por: Margetić, Sandra, et al.
Publicado: (2019)

Antiprothrombin antibodies induce platelet activation: A possible explanation for anti‐FXa therapy failure in patients with antiphospholipid syndrome?
por: Chayoua, Walid, et al.
Publicado: (2021)

Design, Synthesis, and Biological Evaluation of Novel Nitrogen Heterocycle-Containing Ursolic Acid Analogs as Antitumor Agents
por: Wang, Wenzhi, et al.
Publicado: (2019)

Design, synthesis and biological evaluation of novel diarylpyridine derivatives as tubulin polymerisation inhibitors
por: Yang, Shanbo, et al.
Publicado: (2022)

Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition
por: Han, Han, et al.
Publicado: (2021)

Design, synthesis and biological evaluation of selective survivin inhibitors
por: Xiao, Min, et al.
Publicado: (2019)

Design, Synthesis, and Biological Evaluation of Benzimidazole Derivatives as Potential Lassa Virus Inhibitors
por: Chen, Jinwei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9ojagi3t2r3fmgtq4lmbcj1etj